Theragnostics Strengthens Board of Directors with Key Appointments

Drug Development Experts Dr Dennis Langer and Professor Ken Herrmann Appointed as Non-Executive Directors

LONDONAug. 4, 2021 /PRNewswire/ — Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces today the appointments of Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to its Board.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH